AR131398A1 - Tratamiento de enfermedades autoinmunitarias - Google Patents

Tratamiento de enfermedades autoinmunitarias

Info

Publication number
AR131398A1
AR131398A1 ARP230103431A ARP230103431A AR131398A1 AR 131398 A1 AR131398 A1 AR 131398A1 AR P230103431 A ARP230103431 A AR P230103431A AR P230103431 A ARP230103431 A AR P230103431A AR 131398 A1 AR131398 A1 AR 131398A1
Authority
AR
Argentina
Prior art keywords
antibody
nucleic acid
treatment
autoimmune diseases
pad4
Prior art date
Application number
ARP230103431A
Other languages
English (en)
Inventor
Catherine Eugenie Huntington
Katherine Ann Vousden
Gary Sims
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR131398A1 publication Critical patent/AR131398A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos para unirse a PAD y su uso en terapia. Reivindicación 1: Un anticuerpo que comprende un dominio de unión a PAD2 que se une específicamente a PAD2 y/o un dominio de unión a PAD4 que se une específicamente a PAD4. Reivindicación 97: Un polipéptido que comprende el anticuerpo de cualquier reivindicación anterior. Reivindicación 98: Un ácido nucleico que codifica una o más cadenas de un anticuerpo como se define en una cualquiera de las reivindicaciones 1 - 92. Reivindicación 99: Un ácido nucleico que codifica un polipéptido de acuerdo con la reivindicación 93. Reivindicación 100: Un vector que comprende el ácido nucleico de la reivindicación 94 o 95. Reivindicación 101: Una célula hospedadora que comprende el vector de la reivindicación 96. Reivindicación 102: Una composición farmacéutica que comprende un anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 - 92 y un portador farmacéuticamente aceptable. Reivindicación 110: Un anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 - 92 o una composición farmacéutica de acuerdo con la reivindicación 98 para su uso en un método de tratamiento o prevención de una enfermedad en un sujeto.
ARP230103431A 2022-12-19 2023-12-18 Tratamiento de enfermedades autoinmunitarias AR131398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263476066P 2022-12-19 2022-12-19

Publications (1)

Publication Number Publication Date
AR131398A1 true AR131398A1 (es) 2025-03-12

Family

ID=89474788

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230103431A AR131398A1 (es) 2022-12-19 2023-12-18 Tratamiento de enfermedades autoinmunitarias

Country Status (14)

Country Link
US (1) US20240199761A1 (es)
EP (1) EP4638507A1 (es)
JP (1) JP2025542239A (es)
KR (1) KR20250124877A (es)
CN (1) CN120476150A (es)
AR (1) AR131398A1 (es)
AU (1) AU2023413552A1 (es)
CL (1) CL2025001822A1 (es)
CO (1) CO2025009742A2 (es)
CR (1) CR20250284A (es)
IL (1) IL321560A (es)
MX (1) MX2025007229A (es)
TW (1) TW202444762A (es)
WO (1) WO2024133161A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators
WO2026136763A1 (en) 2024-12-19 2026-06-25 Bristol-Myers Squibb Company Genetic predictor for il18 driven disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
JPWO2012026309A1 (ja) * 2010-08-23 2013-10-28 公立大学法人横浜市立大学 抗pad4抗体医薬の創成
JP6057299B2 (ja) 2011-10-31 2017-01-11 国立大学法人 長崎大学 ウイルス感染症の予防又は治療剤
CA2871934C (en) 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
US20150376294A1 (en) 2012-12-03 2015-12-31 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン,エルエルシー 新生児Fc受容体結合が改変されて治療および診断特性が強化された分子
US11447569B2 (en) 2015-03-06 2022-09-20 Public University Corporation Yokohama City University Anti-PAD4 antibody
WO2016155745A1 (en) 2015-03-27 2016-10-06 Rigshospitalet Cross-reactive anti-pad antibodies
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4

Also Published As

Publication number Publication date
IL321560A (en) 2025-08-01
CL2025001822A1 (es) 2025-10-03
JP2025542239A (ja) 2025-12-25
CR20250284A (es) 2025-08-29
KR20250124877A (ko) 2025-08-20
US20240199761A1 (en) 2024-06-20
CO2025009742A2 (es) 2025-08-08
MX2025007229A (es) 2025-07-01
WO2024133161A1 (en) 2024-06-27
TW202444762A (zh) 2024-11-16
CN120476150A (zh) 2025-08-12
AU2023413552A1 (en) 2025-07-31
EP4638507A1 (en) 2025-10-29

Similar Documents

Publication Publication Date Title
AR045056A1 (es) Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
JOP20240279A1 (ar) أجسام مضادة تربط إنترليوكين 13 وطرق الاستخدام
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
BRPI0512911A (pt) anticorpo humano isolado, ácido nucléico, vetor, célula, método de produzir um anticorpo anti-kir humano, composição farmacêutica, e, método de potenciar a atividade da célula nk em um paciente em necessidade do mesmo
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
CO2022017445A2 (es) Proteínas multiespecíficas
JOP20230109A1 (ar) أجسام مضادة ثقيلة السلسلة ترتبط مع مستقبل ألفا فولات
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
MX2023015469A (es) Metodos y composiciones para estimular la actividad inmunitaria.
BR112014026088A2 (pt) produto de tratamento de tecidos, estojo, método de fabricação de um produto de tratamento de tecidos, método de tratamento, e uso do produto de tratamento de tecidos
AR102595A1 (es) Anticuerpos anti-ang2 y métodos de utilización
JOP20220193A1 (ar) صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها
AR083546A1 (es) Tratamiento de inflamacion gastrointestinal, soriasis y asma
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
PE20251075A1 (es) Anticuerpos que se unen a la pad4 humana y usos de los mismos
BR112016007592A2 (pt) proteína de ligação biespecífica que se liga a pelo menos dois alvos, conjugado de proteína de ligação biespecífica, composição farmacêutica, ácido nucleico isolado, vetor, célula hospedeira, método para produzir uma proteína de ligação biespecífica, método para determinar a reatividade de um paciente a um agente terapêutico que tem capacidade para modular a atividade de um tlr, método para ativar ou inibir células responsivas a tlr9, método para tratar um paciente que precisa de ativação de tlr9 ou inibição de tlr e método para identificar um inibidor ou estimulador de sinalização de tlr
CO2025009742A2 (es) Tratamiento de la enfermedad autoinmunitaria
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
CL2025003377A1 (es) Tratamiento de afecciones inflamatorias que comprende imu-856.
MX2024001834A (es) Metodos para tratar el cancer de vejiga no muscular invasivo (nmibc) con conjugados de anticuerpos y farmacos (adc) que se unen a las proteinas 191p4d12.
PY2204506A (es) Anticuerpos antiglicoproteína de espiga y su uso terapéutico
AR104721A1 (es) Fragmento fab anti-ngf humano